Since ANGPTL3, ANGPTL4, and ANGPTL8 are all LPL inhibitors, the absence of anyone of them would break the balance of triglyceride metabolism in turn would lead to hypotriglyceridemia or hypertriglyceridemia. Here, ANGPTL3 is linked to hypertriglyceridemia.